Joseph Geraci
Chief Tech/Sci/R&D Officer bij NETRAMARK HOLDINGS INC.
Vermogen: 932 535 $ op 31-03-2024
Profiel
Joseph Geraci is the founder of NetraMark Corp., which was founded in 2016.
He holds the title of Chief Executive Officer at NetraMark Corp.
Dr. Geraci's current job is as a Director, Chief Scientific & Technology Officer at NetraMark Holdings, Inc. Dr. Geraci's former job was as the Chief Scientific Officer at Open Source Health, Inc. Dr. Geraci has a doctorate degree from the University of Southern California and graduate and doctorate degrees from the University of Toronto.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
NETRAMARK HOLDINGS INC
6.01% | 28-03-2024 | 4 002 298 ( 6.01% ) | 932 535 $ | 31-03-2024 |
Actieve functies van Joseph Geraci
Bedrijven | Functie | Begin |
---|---|---|
NETRAMARK HOLDINGS INC. | Chief Tech/Sci/R&D Officer | 18-10-2021 |
NetraMark Corp.
NetraMark Corp. Information Technology ServicesTechnology Services Part of NetraMark Holdings, Inc., NetraMark Corp. is an AI and pharma-tech company based in Toronto, CA. NetraMark was acquired by NetraMark Holdings, Inc. on October 18, 2021 for $11.92 million. The private company focuses on developing AI/ML solutions for the pharmaceutical industry, using a novel topology-based algorithm to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. NetraMark's proprietary next-generation AI solutions for pharmaceutical and biotechnology companies allow them to leverage small to large data sets in order to prevent clinical trial failure, identify biomarkers, implement adaptive trials, accelerate drug discovery, and enable drug repurposing and resurrection. The Canadian company was founded in 2016 by Joseph Geraci and Richard Brooks, with Joseph Geraci serving as CEO since then. | Chief Executive Officer | 01-01-2016 |
Eerdere bekende functies van Joseph Geraci
Bedrijven | Functie | Einde |
---|---|---|
Open Source Health, Inc.
Open Source Health, Inc. Financial ConglomeratesFinance Open Source Health, Inc. operates as a capital pool company. The company was founded by Sonya Satveit and is headquartered in Calgary, Canada. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Joseph Geraci
University of Southern California | Doctorate Degree |
University of Toronto | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
NETRAMARK HOLDINGS INC. | Technology Services |
Bedrijven in privébezit | 2 |
---|---|
Open Source Health, Inc.
Open Source Health, Inc. Financial ConglomeratesFinance Open Source Health, Inc. operates as a capital pool company. The company was founded by Sonya Satveit and is headquartered in Calgary, Canada. | Finance |
NetraMark Corp.
NetraMark Corp. Information Technology ServicesTechnology Services Part of NetraMark Holdings, Inc., NetraMark Corp. is an AI and pharma-tech company based in Toronto, CA. NetraMark was acquired by NetraMark Holdings, Inc. on October 18, 2021 for $11.92 million. The private company focuses on developing AI/ML solutions for the pharmaceutical industry, using a novel topology-based algorithm to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. NetraMark's proprietary next-generation AI solutions for pharmaceutical and biotechnology companies allow them to leverage small to large data sets in order to prevent clinical trial failure, identify biomarkers, implement adaptive trials, accelerate drug discovery, and enable drug repurposing and resurrection. The Canadian company was founded in 2016 by Joseph Geraci and Richard Brooks, with Joseph Geraci serving as CEO since then. | Technology Services |